Disodium monofluorophosphate

CAS No. 10163-15-2

Disodium monofluorophosphate( —— )

Catalog No. M10085 CAS No. 10163-15-2

Sodium Monofluorophosphate is a competitive inhibitor of pyruvate kinase and alkaline phosphatase with Ki of 3.4 mM and 69 μM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G 27 In Stock

Biological Information

  • Product Name
    Disodium monofluorophosphate
  • Note
    Research use only, not for human use.
  • Brief Description
    Sodium Monofluorophosphate is a competitive inhibitor of pyruvate kinase and alkaline phosphatase with Ki of 3.4 mM and 69 μM, respectively.
  • Description
    Sodium Monofluorophosphate is a competitive inhibitor of pyruvate kinase and alkaline phosphatase with Ki of 3.4 mM and 69 μM, respectively, which also irreversibly inhibits phosphorylase phosphatase with Ki of 0.5 mM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Phosphatase
  • Recptor
    phosphorylase phosphatase| alkaline phosphatase| pyruvate kinase
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    10163-15-2
  • Formula Weight
    143.95
  • Molecular Formula
    FNa2O3P
  • Purity
    >98% (HPLC)
  • Solubility
    Water: 29 mg/mL (201.45 mM)
  • SMILES
    [O-]P([O-])(F)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Pearce EI. Caries Res, 1983, Suppl 1, 21-35.
molnova catalog
related products
  • Voclosporin

    Voclosporin (ISAtx-247) is a novel, orally available calcium-modulated phosphatase (CN; PP2B) inhibitor and immunosuppressant used for treating lupus nephritis.

  • Ertiprotafib

    Ertiprotafib (PTP 112), a selective and potent inhibitor of protein tyrosine phosphate 1B (PTP1B) and IkappaB kinase β (IKK-β), is a novel insulin sensitizer with potential anticancer activity for the study of type 2 diabetes and breast cancer.

  • KLH45

    KLH45 is an effective and selective inhibitor of Spastic Paraplegia-Related Triglyceride Hydrolase DDHD2(IC50 = 1.3 nM).